ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 YTD Q3 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2025-10-01 to 2026-06-30

Swipe to see the full flow
ARROWHEAD PHARMACEUTICALS, INC. cash flow reconciliation, Oct 1, 2025 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from issuance of convertible notes → financing reconciliation: $700,000,000.00Proceeds from issuance of common stock - Underwriting Public Offering → financing reconciliation: $130,000,000.00Proceeds from issuance of warrants → financing reconciliation: $99,998,000.00Proceeds from issuance of common stock - ATM Agreement → financing reconciliation: $76,109,000.00Proceeds from the exercises of stock options → financing reconciliation: $12,763,000.00financing reconciliation → Net cash from financing activities: $780,518,000.00financing reconciliation → Repayments of credit facility: $117,891,000.00financing reconciliation → Purchase of capped calls: $47,880,000.00financing reconciliation → Dividends paid by variable interest entity to noncontrolling shareholders: $38,434,000.00financing reconciliation → Payments of debt issuance costs: $18,716,000.00financing reconciliation → Payments of issuance costs of common stock - Underwriting Public Offering: $13,393,000.00financing reconciliation → Payments of issuance costs of common stock - ATM Agreement: $2,038,000.00Proceeds from maturities of available-for-sale securities → investing reconciliation: $224,152,000.00Proceeds from sales of available-for-sale securities → investing reconciliation: $48,788,000.00investing reconciliation → Purchases of available-for-sale securities: $1,138,714,000.00investing reconciliation → Purchases of property, plant and equipment: $8,567,000.00Net cash used in operating activities → operating reconciliation: $79,546,000.00Deferred revenue → operating reconciliation: $123,940,000.00Stock-based compensation → operating reconciliation: $50,913,000.00Non-cash interest expense on credit facility → operating reconciliation: $44,374,000.00Non-cash interest expense on liability related to the sale of future royalties → operating reconciliation: $25,115,000.00Depreciation and amortization → operating reconciliation: $19,417,000.00Accounts payable → operating reconciliation: $9,980,000.00Loss on equity method investment → operating reconciliation: $9,190,000.00Amortization of convertible notes issuance costs → operating reconciliation: $1,423,000.00Non-cash transfer of property and equipment to affiliate → operating reconciliation: $579,000.00operating reconciliation → Net (loss) income: $288,249,000.00operating reconciliation → Prepaid expenses and other current assets: $29,940,000.00operating reconciliation → Gain on VIE's sale of IPR&D assets: $19,000,000.00operating reconciliation → Accrued expenses: $15,214,000.00operating reconciliation → Accretion of available-for-sale securities premiums/discounts: $4,122,000.00operating reconciliation → Operating lease, net: $3,556,000.00operating reconciliation → Other: $2,453,000.00operating reconciliation → Accounts receivable: $1,907,000.00operating reconciliation → Realized gain on investments: $36,000.00Net cash used in investing activities → investing reconciliation: $874,341,000.00Difference in the filed cash totals (calculated) → Cash sources and uses: $1,580,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $226,548,000.00Net cash from financing activities → Cash sources and uses: $780,518,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $54,759,000.00Cash sources and uses → Net cash used in investing activities: $874,341,000.00Cash sources and uses → Net cash used in operating activities: $79,546,000.00Net (loss) income: -$288,249,000.00Net (loss) income−$288.25 MStock-based compensation: $50,913,000.00Stock-based compensation+$50.91 MDepreciation and amortization: $19,417,000.00Depreciation & amortization+$19.42 MAccretion of available-for-sale securities premiums/discounts: -$4,122,000.00Securities accretion, net−$4.12 MAmortization of convertible notes issuance costs: $1,423,000.00Debt issuance cost amortization+$1.42 MRealized gain on investments: -$36,000.00Realized investment gain & loss−$36.00 KNon-cash interest expense on liability related to the sale of future royalties: $25,115,000.00Non-cash royalty interest+$25.12 MNon-cash interest expense on credit facility: $44,374,000.00Paid-in-kind interest+$44.37 MLoss on equity method investment: $9,190,000.00Equity-method results+$9.19 MGain on VIE's sale of IPR&D assets: -$19,000,000.00Asset disposal gain & loss−$19.00 MNon-cash transfer of property and equipment to affiliate: $579,000.00Non-cash PP&E to affiliate+$579.00 KAccounts receivable: -$1,907,000.00Accounts receivable−$1.91 MPrepaid expenses and other current assets: -$29,940,000.00Prepaid & other assets−$29.94 MAccounts payable: $9,980,000.00Accounts payable+$9.98 MAccrued expenses: -$15,214,000.00Accrued liabilities−$15.21 MDeferred revenue: $123,940,000.00Deferred revenue+$123.94 MOperating lease, net: -$3,556,000.00Operating lease liabilities−$3.56 MOther: -$2,453,000.00Other working capital, net−$2.45 MNet cash used in operating activities: -$79,546,000.00. Cash required to fund net payments.Operating cash−$79.55 Moperating reconciliation: $364,477,000.00Proceeds from the exercises of stock options: $12,763,000.00Stock option exercises+$12.76 MProceeds from issuance of warrants: $99,998,000.00Warrants issued+$100.00 MProceeds from issuance of convertible notes: $700,000,000.00Convertible debt issued+$700.00 MPayments of debt issuance costs: -$18,716,000.00Debt issuance costs−$18.72 MPurchase of capped calls: -$47,880,000.00Capped call purchases−$47.88 MProceeds from issuance of common stock - ATM Agreement: $76,109,000.00Common stock issued: ATM+$76.11 MProceeds from issuance of common stock - Underwriting Public Offering: $130,000,000.00Common stock issued: offering+$130.00 MRepayments of credit facility: -$117,891,000.00Long-term credit line repayments−$117.89 MDividends paid by variable interest entity to noncontrolling shareholders: -$38,434,000.00Noncontrolling dividends−$38.43 MPayments of issuance costs of common stock - ATM Agreement: -$2,038,000.00Stock issuance costs: ATM−$2.04 MPayments of issuance costs of common stock - Underwriting Public Offering: -$13,393,000.00Stock issuance costs: offering−$13.39 MProceeds from Visirna credit agreement: $0.00Net cash from financing activities: $780,518,000.00Financing cash+$780.52 Mfinancing reconciliation: $1,018,870,000.00Purchases of property, plant and equipment: -$8,567,000.00PP&E purchases−$8.57 MPurchases of available-for-sale securities: -$1,138,714,000.00AFS securities purchases−$1.14 BProceeds from sales of available-for-sale securities: $48,788,000.00AFS securities sales+$48.79 MProceeds from maturities of available-for-sale securities: $224,152,000.00AFS securities maturities+$224.15 MNet cash used in investing activities: -$874,341,000.00. Cash required to fund net payments.Investing cash−$874.34 Minvesting reconciliation: $1,147,281,000.00Cash sources and uses: $1,008,646,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $226,548,000.00Beginning cash$226.55 MEnding cash: Cash, cash equivalents, and restricted cash: $54,759,000.00Ending cash$54.76 MDifference in the filed cash totals (calculated): $1,580,000.00Filer's cash difference(calculated)+$1.58 MCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$288.25M + net operating adjustments $208.70M = operating cash −$79.55MFree cash flow−$88.11 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$171.79 MEnding cash − beginning cash
Chart details

ARROWHEAD PHARMACEUTICALS, INC. cash flow reconciliation, Oct 1, 2025 through Jun 30, 2026

Cash flows for Oct 1, 2025 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Sep 30, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Sep 30, 2025
226,548,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 79,546,000 US dollars. Net cash used.
Net (loss) income
negative 288,249,000 US dollars
Stock-based compensation
50,913,000 US dollars
Depreciation and amortization
19,417,000 US dollars
Accretion of available-for-sale securities premiums/discounts
negative 4,122,000 US dollars
Amortization of convertible notes issuance costs
1,423,000 US dollars
Realized gain on investments
negative 36,000 US dollars
Non-cash interest expense on liability related to the sale of future royalties
25,115,000 US dollars
Non-cash interest expense on credit facility
44,374,000 US dollars
Loss on equity method investment
9,190,000 US dollars
Gain on VIE's sale of IPR&D assets
negative 19,000,000 US dollars
Non-cash transfer of property and equipment to affiliate
579,000 US dollars
Accounts receivable
negative 1,907,000 US dollars
Prepaid expenses and other current assets
negative 29,940,000 US dollars
Accounts payable
9,980,000 US dollars
Accrued expenses
negative 15,214,000 US dollars
Deferred revenue
123,940,000 US dollars
Operating lease, net
negative 3,556,000 US dollars
Other
negative 2,453,000 US dollars
Investing activities
negative 874,341,000 US dollars. Net cash used.
Purchases of property, plant and equipment
negative 8,567,000 US dollars
Purchases of available-for-sale securities
negative 1,138,714,000 US dollars
Proceeds from sales of available-for-sale securities
48,788,000 US dollars
Proceeds from maturities of available-for-sale securities
224,152,000 US dollars
Financing activities
780,518,000 US dollars. Net cash provided.
Proceeds from the exercises of stock options
12,763,000 US dollars
Proceeds from issuance of warrants
99,998,000 US dollars
Proceeds from issuance of convertible notes
700,000,000 US dollars
Payments of debt issuance costs
negative 18,716,000 US dollars
Purchase of capped calls
negative 47,880,000 US dollars
Proceeds from issuance of common stock - ATM Agreement
76,109,000 US dollars
Proceeds from issuance of common stock - Underwriting Public Offering
130,000,000 US dollars
Repayments of credit facility
negative 117,891,000 US dollars
Dividends paid by variable interest entity to noncontrolling shareholders
negative 38,434,000 US dollars
Payments of issuance costs of common stock - ATM Agreement
negative 2,038,000 US dollars
Payments of issuance costs of common stock - Underwriting Public Offering
negative 13,393,000 US dollars
Proceeds from Visirna credit agreement
0 US dollars
Operating adjustment reconciliation
364,477,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
1,018,870,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
1,147,281,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Difference in the filed cash totals (calculated)
1,580,000 US dollars. Into cash; drawn as the small gray flow above beginning cash.
Ending cash on Jun 30, 2026
54,759,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
1,008,646,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 171,789,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 79,546,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
8,567,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 88,113,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$288.25M + net operating adjustments $208.70M = operating cash −$79.55M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • The filer's reported cash figures differ by $1.58 M: its ending cash less its beginning cash does not equal its reported net change in cash. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 79,546,000 US dollars minus 8,567,000 US dollars equals negative 88,113,000 US dollars.
  • The filer's reported cash figures differ by $1.58 M: its ending cash less its beginning cash does not equal its reported net change in cash. The chart shows the difference as its own calculated flow; no reported amount has been adjusted.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 YTD Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!